Albendazole 400 Mg Tablets – Antiparasitic Medicine & Cancer Drug Repurposing Research
Price range: $24.00 through $60.00
Albendazole 400 Mg is a broad-spectrum antiparasitic medication commonly used in human medicine to treat infections caused by intestinal worms and other helminths. It belongs to the benzimidazole class of drugs and works by inhibiting the parasite’s ability to absorb glucose, leading to energy depletion and eventual parasite death. Albendazole is widely prescribed for conditions such as roundworm, hookworm, pinworm infections, neurocysticercosis, and hydatid disease caused by tapeworm larvae.
Beyond its established role in treating parasitic infections, Albendazole has also gained attention in scientific research exploring drug repurposing in oncology. Preclinical studies suggest that Albendazole may interfere with microtubule formation in rapidly dividing cells, which could potentially inhibit tumor growth and trigger apoptosis in certain cancer cell lines. However, these findings remain investigational, and Albendazole is not currently approved as a standard cancer treatment.
For medical safety, Albendazole should always be used under the supervision of a qualified healthcare professional, especially in long-term therapies where monitoring of liver function may be recommended.
Description
Albendazole 400 Mg Tablets and Cancer Drug-Repurposing Research
Albendazole 400 Mg Tablets contain albendazole, a benzimidazole anthelmintic medicine with an established history of use against susceptible parasitic worm infections. Beyond its conventional antiparasitic applications, albendazole has attracted scientific interest as a potential repurposed medicine for oncology research.
Drug repurposing involves investigating medicines that are already known and established for one medical purpose to determine whether they may have additional therapeutic applications. Researchers have investigated albendazole’s potential anticancer properties in laboratory models, animal studies and early clinical research.
Proposed mechanisms include interference with microtubule function, disruption of cancer-cell division, cell-cycle arrest and induction of apoptosis. Reviews of benzimidazole drug repurposing have identified albendazole as a compound of interest for further anticancer investigation, while also emphasizing the need for additional controlled clinical research.
Albendazole and Cancer Research
Scientific research has investigated albendazole in relation to several types of cancer.
Head and neck cancer: Preclinical research has examined albendazole in head and neck squamous cell cancer models, reporting effects involving cancer-cell proliferation, cell-cycle progression and apoptosis. These findings provide a basis for further investigation but do not establish albendazole as a standard treatment for head and neck cancer.
Colorectal cancer: Research has also investigated albendazole in colorectal cancer models. A 2024 study examined its effects in colorectal cancer cells, animal tumor models and patient-derived organoids, reporting findings involving RNF20 and apoptosis. These results support continued investigation into the potential anticancer mechanisms of albendazole.
Melanoma: Experimental research has examined albendazole in melanoma models, including its potential effects on cancer-cell proliferation, G2/M cell-cycle arrest and apoptosis.
These findings should be interpreted in the context of the available evidence. Results from laboratory and animal studies do not necessarily demonstrate that the same effects will occur in human patients.
Albendazole belongs to the same broad benzimidazole class as mebendazole. To understand their differences, clinical applications and treatment considerations, read Albendazole vs Mebendazole: Which Deworming Medicine Works Better?
Clinical Research With Albendazole in Cancer
Albendazole has also been investigated in early-stage human cancer research.
A Phase I clinical study evaluated oral albendazole in 36 patients with refractory solid tumors. The study primarily examined safety, tolerability and pharmacokinetics while also exploring potential biological activity. Myelosuppression was identified as the principal dose-limiting toxicity, with fatigue and gastrointestinal effects also reported.
This early clinical investigation is important when considering albendazole’s potential for drug repurposing. However, a Phase I study is not sufficient to establish effectiveness as a cancer treatment or to determine that albendazole should replace established oncology therapies.
How Might Albendazole Affect Cancer Cells?
Researchers have proposed several mechanisms that may contribute to the potential anticancer activity observed in experimental studies.
These include:
- Disruption of microtubule dynamics
- Interference with cancer-cell division
- G2/M cell-cycle arrest
- Induction of apoptosis
- Potential effects on angiogenesis
- Modulation of pathways associated with tumor growth and survival
- Potential effects on cancer-cell migration
Much of the evidence supporting these mechanisms remains preclinical, including laboratory and animal research. Further clinical studies are necessary to determine whether these mechanisms translate into meaningful benefits for people with cancer.
Is Albendazole 400 Mg an Approved Cancer Treatment?
Albendazole 400 Mg Tablets should not be described as an established or approved general cancer treatment.
Albendazole’s established medical application is as an antiparasitic medicine. Its potential use in oncology remains an area of drug-repurposing research and clinical investigation.
Cancer patients should not replace chemotherapy, immunotherapy, targeted therapy, radiation therapy, surgery or other evidence-based cancer treatments with albendazole.
Individuals considering an investigational or off-label use of albendazole should discuss the potential risks, benefits, drug interactions and appropriate monitoring with their oncologist or another qualified healthcare professional.
Why Is Albendazole Being Investigated for Drug Repurposing?
Drug repurposing provides researchers with an opportunity to investigate existing medicines for potential applications beyond their original indications.
Albendazole is of interest because its established pharmacological activity and effects on cellular microtubules provide a scientific basis for investigating whether it could influence certain cancer-related cellular processes.
Current research supports continued investigation, but additional well-designed clinical studies are required to establish whether albendazole has meaningful anticancer efficacy, determine appropriate oncology dosing, evaluate long-term safety and identify which patient populations, if any, could benefit.
Albendazole 400 Mg: Research vs Established Medical Use
| Area | Current Evidence |
|---|---|
| Antiparasitic use | Established medical use |
| Cancer-cell laboratory research | Investigated |
| Animal cancer models | Investigated |
| Early clinical cancer research | Investigated |
| Approved general cancer treatment | Not established |
| Replacement for standard cancer therapy | Not recommended |
Albendazole 400 Mg is commonly used to treat infections caused by parasitic worms. It belongs to the benzimidazole class of medications and works by disrupting the parasite’s ability to absorb nutrients and maintain cellular structure. This process eventually leads to parasite death. Albendazole is widely used in global parasite control programs and in clinical treatment of infections such as neurocysticercosis and hydatid disease. In addition to its antiparasitic effects, researchers have investigated albendazole in laboratory studies to explore whether it may influence cancer cell growth through microtubule disruption mechanisms.
Albendazole works by binding to β-tubulin proteins inside parasite cells. Tubulin proteins assemble into microtubules, which are necessary for cell division and nutrient transport. When albendazole interferes with tubulin polymerization, parasite cells lose their ability to absorb glucose and produce energy. This disruption causes energy depletion and eventually leads to parasite death. The same microtubule-targeting mechanism is the reason researchers have investigated albendazole’s effects on rapidly dividing cancer cells in laboratory experiments.
Several studies have shown that Albendazole can inhibit cancer cell proliferation and induce apoptosis in certain tumor cell lines, including colon and pancreatic cancer cells. However, these findings mainly come from laboratory experiments and animal studies. More clinical trials involving human patients are needed before Albendazole could be recommended for oncology treatment.
Albendazole has attracted scientific interest because it interferes with microtubules, which are essential structures required for cell division. Many anticancer drugs work by targeting microtubules to stop tumor cells from multiplying. Laboratory studies have demonstrated that albendazole can disrupt microtubule formation and induce apoptosis in several cancer cell models. These findings have encouraged researchers to investigate whether albendazole could potentially be repurposed for oncology applications in experimental studies.
Albendazole is approved for treating parasitic infections in humans. However, it is not approved as a cancer treatment by regulatory agencies such as the FDA. While laboratory studies have shown interesting biological effects on tumor cells, additional clinical trials are required before albendazole could be considered for oncology use.
Albendazole is commonly used to treat infections caused by several types of parasitic worms, including roundworms, hookworms, tapeworms, and certain tissue parasites. It is frequently used to treat conditions such as hydatid disease and neurocysticercosis. Its broad spectrum of activity has made it one of the most widely used antiparasitic medications in many countries.
RELATED PRODUCTS
Fenbendazole 222 Mg Tablets
Fenbendazole Cream
Fenbendazole Tablets 1000 Mg – Wormentel
Iverheal 12 mg – Ivermectin
Iverheal 6 Mg – Ivermectin
Ivermectin Tablets 40mg
Reviews
There are no reviews yet.